Upadacitinib may offer superior disease management than tofacitinib for patients with ulcerative colitis. Learn more.

Researchers have uncovered potentially diagnostic gut microbiome signatures and metabolic pathways associated specifically ...

Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis ...

diff) is a bacterial infection that commonly affects people with ulcerative colitis (UC ... so you may need to change or intensify your treatment plan. People with UC and C.

In a year of pivotal gastroenterology research, these 10 articles were in a class of their own, according to Dr David Johnson ...

Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...

In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first ...

Officially Benefiting Mainland China PatientsSHANGHAI, Dec 18, 2024 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK, ...

Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as ... are generally only used in short courses for ...

Denosumab biosimilar is under clinical development by Samsung Bioepis and currently in Phase III for Post Menopausal Osteoporosis.

By automating certain tasks, such as clinical documentation, AI allows healthcare providers to focus more on the patient ...

Patients with inflammatory bowel disease (IBD) reported mostly favorable responses with the use of mail-order kits for stool ...